$CLNN News
Last published 1w ago
- 1w agoCLNNClene Inc. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoCLNNClene Reports Third Quarter 2026 Financial Results and Recent Operating HighlightsGlobeNewswireSubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in October 2026 seeking accelerated approval for CNM-Au8® in amyotrophic lateral sclerosis (ALS) Completed a $4.0 million registered
- 3w agoCLNNClene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALSGlobeNewswireNDA submission seeks accelerated approval of CNM-Au8 based on neurofilament light chain biomarker data and clinical outcomes SALT LAKE CITY, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN), a
- 1mo agoCLNNClene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDAGlobeNewswireInvestment was led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders$4 million registered direct
- 1mo agoCLNNClene Announces $4 Million Registered Direct OfferingGlobeNewswireInvestment led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders$4 million registered direct offering
- 2mo agoQNTMSNYRHHBYBIIB+1A Micro-Cap Biotech Just Cleared a Milestone Most Never ReachGlobeNewswireAUSTIN, Texas, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis ("MS") drugs on the market today can slow the disease down, but none of them stop it, and none of them give
- 2mo agoCLNNClene to Present at Upcoming September Investor ConferencesGlobeNewswireSALT LAKE CITY, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) today announced that management will present at the 2026 Cantor Global Healthcare Conference and at the H.C. Wainwright 28th Annual Global
- 2mo agoCLNNEXTRAORDINARY MEETING OF SHAREHOLDERS - CLENE INCEarnings Call TranscriptsGood afternoon. It is 2 p.m. UK time on Monday, 24 August, 2026. I am Tamir Saeed, Chairman of Air Global PLC, and I am pleased to welcome shareholders to this extraordinary general meeting of the company. I will be acti
- 2mo agoCLNNEmerging Growth Conference 95 - CLENE INCEarnings Call TranscriptsThank you for watching. Thank you. Thank you. We'll be right back. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Piano music Thank you
- 2mo agoCLNNEmerging Growth Conference 95 - CLENE INCEarnings Call TranscriptsThank you for watching. Thank you. Thank you. We'll be right back. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Piano music Thank you
- 2mo agoMWCSBCNPMMFSKHRF+20Presenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live streamGlobeNewswireMIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 95th Emerging Growth Conference on August 19 & 20, 2026. The Emerging Growth
- 2mo agoMWCSBCNPMMFSKHRF+20Presenting on Emerging Growth Conference 95 Day 1 on August 19; Register to live streamGlobeNewswireMIAMI, Aug. 18, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 95th Emerging Growth Conference on August 19 & 20, 2026. The Emerging
- 2mo agoCLNNClene to Present at the Emerging Growth ConferenceGlobeNewswireSALT LAKE CITY, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) today announced that management will present at the Emerging Growth Conference. Virtual Presentation DetailsDate: August 19, 2026Time of
- 2mo agoCLNNSpecial Meeting of Stockholders - CLENE INCEarnings Call TranscriptsWelcome to the August 2026 Special Meeting of Stockholders of Enview Medical, Inc. I would now like to introduce Doron Besser, MD, Chief Executive Officer and Director of EnView Medical, Incorporated. Good morning. I am
- 2mo agoCLNNClene Reports Second Quarter 2026 Financial Results and Recent Operating HighlightsGlobeNewswireClene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026Clene announces survival and functional benefit in CNM-Au8-treated patients whose
- 3mo agoCLNNCG 46TH ANNUAL GROWTH CONFERENCE - CLENE INCEarnings Call TranscriptsGood morning, everyone. I'm Samanth Kulkarni, a Senior Biotechnology Analyst at Canaccord Genuity, and I'd like to thank all our institutional clients for your ongoing support of our equity research franchise and efforts
- 3mo agoCLNNCG 46TH ANNUAL GROWTH CONFERENCE - CLENE INCEarnings Call TranscriptsGood morning, everyone. I'm Samanth Kulkarni, a Senior Biotechnology Analyst at Canaccord Genuity, and I'd like to thank all our institutional clients for your ongoing support of our equity research franchise and efforts
- 3mo agoCLNNSOW GOOD INC. SPECIAL MEETING OF STOCKHOLDERS - CLENE INCEarnings Call TranscriptsGood morning, ladies and gentlemen. Welcome to the special meeting, meeting of stockholders of So Good, Inc. I'm Yusro Goldberg, the chief executive officer of the company. At this time, I call the meeting to order. Here
- 3mo agoCLNNClene Announces Biomarker Analyses To Be Included in NDA Submission Supporting ALS Accelerated ApprovalGlobeNewswireSurvival benefit is concentrated in participants with NfL biomarker response: CNM-Au8®-treated patients whose NfL declined or stabilized lived significantly longer than concurrently randomized controlsFunctional benefit
- 3mo agoCLNNWALDENCAST PLC ANNUAL GENERAL MEETING OF SHAREHOLDERS - CLENE INCEarnings Call TranscriptsAs the time is now one minute past five, I would like to welcome you to the Annual General Meeting of WaldenCat PLC, for those attending in person, as well as those shareholders who are listening electronically. Please n
- 3mo agoCLNNClene to Present at The Canaccord 46th Annual Growth ConferenceGlobeNewswireSALT LAKE CITY, July 29, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage
- 4mo agoQNTMSNYRHHBYBIIB+1Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple SclerosisGlobeNewswireAUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis ("MS") robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9
- 6mo agoCLNNClene Reports First Quarter 2026 Financial Results and Recent Operating HighlightsGlobeNewswireAfter successful completion of FDA Type C meeting, Clene expects to submit an NDA for CNM-Au8® under the accelerated approval pathway in the third quarter of 2026In January 2026, Clene completed an oversubscribed
- 6mo agoCLNNClene Announces $7 Million Underwritten Offering of Common StockGlobeNewswireSALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene" or the "Company") and its wholly owned subsidiary, Clene Nanomedicine, Inc., a late clinical-stage
- 6mo agoCLNNClene to Present at Upcoming May ConferencesGlobeNewswireSALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company
- 6mo agoCLNNAfter Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALSGlobeNewswireFDA stated that the "proposed data may be capable of supporting the submission and review of an [NDA] under the accelerated approval pathway" for CNM-Au8 based on neurofilament light (NfL) biomarker dataFDA acknowledged
- 8mo agoCLNNCLENE INC., (NASDAQ: CLNN) - CLENE INCEarnings Call TranscriptsWelcome back, everyone. Next, we have Clean Inc. trades on the NASDAQ under the symbol CLNN. It's a late clinical stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function
- 8mo agoCLNNClene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 CatalystsGlobeNewswireOperating capital runway sufficient into the fourth quarter of 2026 In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8 data submitted in late 2025Anticipated
- 8mo agoCLNNClene to Present at the Emerging Growth ConferenceGlobeNewswireSALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company
- 9mo agoCBBHFCEIEFCLNNCOPAF+26Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live streamGlobeNewswireMIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 89th Emerging Growth Conference on January 21 & 22, 2026. The Emerging Growth
- 9mo agoCLNNClene to Present at the Emerging Growth ConferenceGlobeNewswireSALT LAKE CITY, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company
- 10mo agoCLNNClene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA MeetingGlobeNewswireThe FDA has granted an in-person Type C meeting during the first quarter of 2026 New independent analyses across large observational ALS cohorts demonstrate that modest (~10%) NfL reductions are significantly associated
- 10mo agoCLNNClene Announces Registered Direct Offering of Over $28 MillionGlobeNewswireOversubscribed registered direct offering priced above market to new, existing and insider investors, including Boxer Capital Management, Coastlands Capital, and Vivo CapitalInitial financing tranche of over $6 million,
- 11mo agoCLNNClene to Present at the Emerging Growth ConferenceGlobeNewswireSALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company
- 11mo agoCLNNClene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®GlobeNewswireFDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8Biomarker improvements are strongly associated with longer survival, reinforcing CNM-Au8's
- 11mo agoCLNNClene to Provide CNM-Au8® ALS Program UpdateGlobeNewswireSALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company
- 11mo agoCLNNClene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor ConferenceGlobeNewswireSALT LAKE CITY, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company
- 12mo agoCLNNClene Reports Third Quarter 2025 Financial Results and Recent Operating HighlightsGlobeNewswireAs the U.S. Food and Drug Administration (FDA) proposed, Clene is concluding analyses of its ALS biomarker data with completion planned shortly The FDA advised Clene to request a Type C meeting to review these further
- 1y agoCLNNEmerging Growth Conference 87 - CLENE INCEarnings Call TranscriptsWelcome back. We have an update from Elora Resources. Trades on the OTCQX under the symbol ELRRF and on the TSX under the symbol ELO. It's an exploration and mine development company with a portfolio of gold and base met
- 1y agoCLNNClene to Present at the Emerging Growth ConferenceGlobeNewswireSALT LAKE CITY, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company
- 1y agoCLNNClene to Participate in a Panel Discussion at the Maxim Growth SummitGlobeNewswireSALT LAKE CITY, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company
- 1y agoCLNNClene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis PatientsGlobeNewswireLate-breaking clinical data presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis Across non-active progressive MS (primary progressive and secondary progressive MS), relapsing M
- 1y agoCLNNClene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson's DiseaseGlobeNewswireNovel human preclinical neuronal model for Parkinson's disease demonstrated CNM-Au8's ability to improve mitochondrial health, restore cellular metabolism, reduce inflammation, and normalize dysregulated gene expression
- 1y agoCLNNClene to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireSALT LAKE CITY, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical
- 1y agoADVMCLNNCUAUFDERM+27Presenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live streamGlobeNewswireMIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth
- 1y agoCLNNClene Reports Second Quarter 2025 Financial Results and Recent Operating HighlightsGlobeNewswireFollowing constructive FDA feedback on its proposed statistical analysis plan, Clene plans to analyze the neurofilament light data from its large NIH-sponsored Early Access Protocol early in the fourth quarter of 2025A
- 1y agoCLNNClene to Present at the Emerging Growth ConferenceGlobeNewswireSALT LAKE CITY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company
- 1y agoCLNNClene to Present at the Canaccord 45th Annual Growth ConferenceGlobeNewswireSALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company
- 1y agoCLNNClene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA MeetingsGlobeNewswireFDA provides supportive feedback on proposed statistical analysis plan for neurofilament biomarker analysis of Clene's NIH-sponsored Expanded Access ProgramNfL EAP biomarker analyses to be conducted early in the 4th
- 1y agoCLNNClene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025ACCESS NewswireSALT LAKE CITY, UT / ACCESS Newswire / June 9, 2025 / Clene Inc. announced that Rob Etherington, Chief Executive Officer and President, will be presenting at the Investor Summit Virtual taking place on June 10.About